Scott Dylla

Scott Dylla, co-founder and CSO of StemCentrx, shares his journey from academia to biotech, motivated by his grandmother's battle with leukemia. He discusses the innovative approach of targeting cancer stem cells using antibody-drug conjugates, highlighting the discovery of DLL3 in small cell lung cancer. Dylla also contrasts the dynamics of research in industry versus academia, emphasizing the importance of teamwork in biotech innovation. With a focus on curing cancer, he outlines StemCentrx's mission and therapeutic advancements.